These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 32633157

  • 1. Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study.
    Citterio F, Henry M, Kim DY, Kim MS, Han DJ, Kenmochi T, Mor E, Tisone G, Bernhardt P, Hernandez Gutierrez MP, Watarai Y.
    Expert Opin Drug Saf; 2020 Oct; 19(10):1339-1348. PubMed ID: 32633157
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.
    Sommerer C, Legendre C, Citterio F, Watarai Y, Oberbauer R, Basic-Jukic N, Han J, Gawai A, Bernhardt P, Chadban S.
    Transplantation; 2023 Jul 01; 107(7):1593-1604. PubMed ID: 36959121
    [Abstract] [Full Text] [Related]

  • 3. Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study.
    Watarai Y, Danguilan R, Casasola C, Chang SS, Ruangkanchanasetr P, Kee T, Wong HS, Kenmochi T, Amante AJ, Shu KH, Ingsathit A, Bernhardt P, Hernandez-Gutierrez MP, Han DJ, Kim MS.
    Clin Transplant; 2021 Oct 01; 35(10):e14415. PubMed ID: 34216395
    [Abstract] [Full Text] [Related]

  • 4. An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients.
    Sommerer C, Suwelack B, Dragun D, Schenker P, Hauser IA, Witzke O, Hugo C, Kamar N, Merville P, Junge M, Thaiss F, Nashan B, Athena Study Group.
    Kidney Int; 2019 Jul 01; 96(1):231-244. PubMed ID: 31027892
    [Abstract] [Full Text] [Related]

  • 5. Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study.
    Tedesco-Silva H, Pascual J, Viklicky O, Basic-Jukic N, Cassuto E, Kim DY, Cruzado JM, Sommerer C, Adel Bakr M, Garcia VD, Uyen HD, Russ G, Soo Kim M, Kuypers D, Buchler M, Citterio F, Hernandez Gutierrez MP, Bernhardt P, Chadban S, TRANSFORM Investigators.
    Transplantation; 2019 Sep 01; 103(9):1953-1963. PubMed ID: 30801548
    [Abstract] [Full Text] [Related]

  • 6. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
    Ueno P, Felipe C, Ferreira A, Cristelli M, Viana L, Mansur J, Basso G, Hannun P, Aguiar W, Tedesco Silva H, Medina-Pestana J.
    Transplantation; 2017 Apr 01; 101(4):844-850. PubMed ID: 27490418
    [Abstract] [Full Text] [Related]

  • 7. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study.
    Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutierrez MPH, Marti AM, Bernhardt P, Pascual J, TRANSFORM investigators.
    Am J Transplant; 2019 Nov 01; 19(11):3018-3034. PubMed ID: 31152476
    [Abstract] [Full Text] [Related]

  • 8. Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study.
    Aubert O, Divard G, Pascual J, Oppenheimer F, Sommerer C, Citterio F, Tedesco H, Chadban S, Henry M, Vincenti F, Srinivas T, Watarai Y, Legendre C, Bernhardt P, Loupy A.
    BMJ Open; 2021 Oct 07; 11(10):e052138. PubMed ID: 34620664
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysis
.
    He L, Deng J, Yang B, Jiang W.
    Clin Nephrol; 2018 May 07; 89(5):336-344. PubMed ID: 29292693
    [Abstract] [Full Text] [Related]

  • 10. Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation.
    Pascual J, Berger SP, Witzke O, Tedesco H, Mulgaonkar S, Qazi Y, Chadban S, Oppenheimer F, Sommerer C, Oberbauer R, Watarai Y, Legendre C, Citterio F, Henry M, Srinivas TR, Luo WL, Marti A, Bernhardt P, Vincenti F, TRANSFORM Investigators.
    J Am Soc Nephrol; 2018 Jul 07; 29(7):1979-1991. PubMed ID: 29752413
    [Abstract] [Full Text] [Related]

  • 11. Effect of Calcineurin Inhibitor-Free, Everolimus-Based Immunosuppressive Regimen on Albuminuria and Glomerular Filtration Rate After Heart Transplantation.
    Nelson LM, Andreassen AK, Andersson B, Gude E, Eiskjær H, Rådegran G, Dellgren G, Gullestad L, Gustafsson F.
    Transplantation; 2017 Nov 07; 101(11):2793-2800. PubMed ID: 28230646
    [Abstract] [Full Text] [Related]

  • 12. Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study.
    Gustafsson F, Andreassen AK, Andersson B, Eiskjær H, Rådegran G, Gude E, Jansson K, Solbu D, Karason K, Arora S, Dellgren G, Gullestad L, SCHEDULE (Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance) Investigators*.
    Transplantation; 2020 Jan 07; 104(1):154-164. PubMed ID: 30893292
    [Abstract] [Full Text] [Related]

  • 13. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
    Belliere J, Kamar N, Mengelle C, Allal A, Sallusto F, Doumerc N, Game X, Congy-Jolivet N, Esposito L, Debiol B, Rostaing L.
    Transpl Int; 2016 Mar 07; 29(3):315-22. PubMed ID: 26575959
    [Abstract] [Full Text] [Related]

  • 14. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials.
    Cooper M, Wiseman AC, Zibari G, McCague K, Kim Y, Geissler F, Nashan B.
    Clin Transplant; 2013 Mar 07; 27(6):E625-35. PubMed ID: 24033455
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L, Noble J, Terrec F, Bennani HN, Chevallier E, Janbon B, Germi R, Bugnazet M, Imerzoukene F, Malvezzi P, Rostaing L, Jouve T.
    Int Urol Nephrol; 2021 Mar 07; 53(3):591-600. PubMed ID: 33058036
    [Abstract] [Full Text] [Related]

  • 16. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
    Lim WH, Russ GR, Wong G, Pilmore H, Kanellis J, Chadban SJ.
    Kidney Int; 2017 Apr 07; 91(4):954-963. PubMed ID: 28109543
    [Abstract] [Full Text] [Related]

  • 17. Very Early Introduction of Everolimus in De Novo Liver Transplantation: Results of a Multicenter, Prospective, Randomized Trial.
    Cillo U, Saracino L, Vitale A, Bertacco A, Salizzoni M, Lupo F, Colledan M, Corno V, Rossi G, Reggiani P, Baccarani U, Bresàdola V, De Carlis L, Mangoni I, Ramirez Morales R, Agnes S, Nure E.
    Liver Transpl; 2019 Feb 07; 25(2):242-251. PubMed ID: 30592371
    [Abstract] [Full Text] [Related]

  • 18. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D, Molina-Andujar A, Montagud-Marrahi E, Revuelta I, Rovira J, Ventura-Aguiar P, Piñeiro GJ, De Sousa-Amorim E, Esforzado N, Cofán F, Torregrosa JV, Ugalde-Altamirano J, Ricart MJ, Centellas-Pérez FJ, Solè M, Martorell J, Ríos J, Campistol JM, Diekmann F, Oppenheimer F.
    Transplantation; 2020 Aug 07; 104(8):1686-1694. PubMed ID: 32732848
    [Abstract] [Full Text] [Related]

  • 19. Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients.
    de Boer SE, Sanders JSF, Bemelman FJ, Betjes MGH, Burgerhof JGM, Hilbrands L, Kuypers D, van Munster BC, Nurmohamed SA, de Vries APJ, van Zuilen AD, Hesselink DA, Berger SP.
    BMC Nephrol; 2021 Jun 02; 22(1):208. PubMed ID: 34078323
    [Abstract] [Full Text] [Related]

  • 20. Adequacy of Initial Everolimus Dose, With and Without Calcineurin Inhibitors, in Kidney Transplant Recipients.
    Felipe C, Ferreira A, Bessa A, Abait T, Perez JD, Casarini DE, Medina-Pestana J, Tedesco H.
    Ther Drug Monit; 2018 Feb 02; 40(1):52-58. PubMed ID: 29271815
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.